Rybelsus®

Semaglutide

Rybelsus® tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus® can be prescribed when other diabetes medicines have been tried without success and should be used together with diet and exercise. Rybelsus® tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating.
more
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
BGN 26.08
BGN 2347.02BGN 26.08
BGN 312.77
60 tablet
Free AirMail shipping Hot
BGN 27.82
BGN 1668.97BGN 27.82
BGN 104.23
30 tablet
Free AirMail shipping Hot
BGN 29.55
BGN 886.60BGN 29.55
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
BGN 31.29
BGN 2816.45BGN 31.29
BGN 156.30
60 tablet
Free AirMail shipping Hot
BGN 32.16
BGN 1929.76BGN 32.16
BGN 52.07
30 tablet
Free AirMail shipping Hot
BGN 33.03
BGN 990.92BGN 33.03
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
BGN 37.38
BGN 3364.10BGN 37.38
BGN 156.30
60 tablet
Free AirMail shipping Hot
BGN 38.25
BGN 2294.87BGN 38.25
BGN 52.07
30 tablet
Free AirMail shipping Hot
BGN 39.12
BGN 1173.47BGN 39.12
Rybelsus

Brand(s)

Manufacturer

  • Novo Nordisc India Pvt. Ltd

Disease(s)

  • Type 2 Diabetes Mellitus / High Blood Sugar

Rybelsus® tablets

What is Rybelsus?

Rybelsus tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus can be prescribed when other diabetes medicines have been tried without success, and should be used together with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists.
Rybelsus is not for treating type 1 diabetes.
Rybelsus was first approved by the FDA on September 20, 2019.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.